EUVIMEDEUVIMED entdecken
Crossref

2636-P: Efsubaglutide Alfa in Overweight or Obesity: Phase 2b ENLIGHT Study

YUQIAN BAO, FEI GAO, ZHENHUA LI, YI YANG, YUFAN WANG, ZHIFENG CHENG, LIMING CHEN, JIANZHONG XIAO, YAN WANG, BOWEI LIU, LI YAN, YIBING LU und 5 weitere

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-2636-p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von YUQIAN BAO und 16 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: Efsubaglutide alfa (Suba) is a novel GLP-1RA. ENLIGHT is a seamless Phase 2b/3 program; the Phase 2b stage evaluated Suba regimens to inform dose selection for the subsequent Phase 3 study.

Methods

This double-blind, placebo (PBO)-controlled trial (NCT06921486) randomized participants to Suba 5, 10, or 20 mg once weekly (QW), 20 mg once every 2 weeks (Q2W), or PBO. Treatment started at 1 mg with individualized dose escalation every 2 weeks to reach target doses and continued for a total of 18 weeks. The primary endpoint was percent change in body weight (BW) at end of treatment. Secondary endpoints included BW change (kg), the proportion achieving ≥5% weight loss, and waist circumference (WC). Safety endpoints included TEAEs, vital signs, 12-lead ECG, and laboratory tests.

Results

BW change (%) was −3.61 with PBO and −7.95, −9.99, −10.58, and −9.70 with Suba 5, 10, and 20 mg QW, and 20 mg Q2W; BW change (kg) was −2.88 vs −6.73, −8.59, −9.22, and −8.48. The proportions achieving ≥5% weight loss were 26.8% with PBO and 75.6%, 78.0%, 81.6%, and 73.7% with Suba regimens. WC decreased by −4.35 cm with PBO vs −6.88 to −8.94 cm with Suba. Efficacy was generally dose dependent (20mg Q2W comparable with 10mg QW) (Fig. 1). TEAEs were mostly mild-to-moderate gastrointestinal, with no premature discontinuations or drug-related SAEs.

Conclusion

ENLIGHT regimens (QW and Q2W) produced clinically meaningful weight loss with a favorable safety profile, supporting progression to the Phase 3 stage. Disclosure Y. Bao: None. F. Gao: None. Z. Li: None. Y. Yang: None. Y. Wang: None. Z. Cheng: None. L. Chen: Research Support; Current; AstraZeneca, Lilly, Gan & Lee Pharmaceuticals, Novo Nordisk, Sanofi. J. Xiao: None. Y. Wang: None. B. Liu: None. L. Yan: None. Y. Lu: None. C. Yang: None. H. Chen: None. J. Zhou: None. W. Jia: None. Q. Wang: Board Member; Current; Innogen Pharmaceuticals Technology Co., Ltd. Funding Innogen Pharmaceutical Co. Ltd.

Zitieren

APA

BAO, Y., GAO, F., LI, Z., YANG, Y., WANG, Y., CHENG, Z., CHEN, L., XIAO, J., WANG, Y., LIU, B., YAN, L., LU, Y., YANG, C., CHEN, H., ZHOU, J., JIA, W., & WANG, Q. (2026). 2636-P: Efsubaglutide Alfa in Overweight or Obesity: Phase 2b ENLIGHT Study. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2636-p

Vancouver

BAO Y, GAO F, LI Z, YANG Y, WANG Y, CHENG Z, et al. 2636-P: Efsubaglutide Alfa in Overweight or Obesity: Phase 2b ENLIGHT Study. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2636-p

BibTeX
@article{BAO2026,
  author = {BAO, YUQIAN and GAO, FEI and LI, ZHENHUA and YANG, YI and WANG, YUFAN and CHENG, ZHIFENG and CHEN, LIMING and XIAO, JIANZHONG and WANG, YAN and LIU, BOWEI and YAN, LI and LU, YIBING and YANG, CAIXIAN and CHEN, HONG and ZHOU, JIAN and JIA, WEIPING and WANG, QINGHUA},
  title = {2636-P: Efsubaglutide Alfa in Overweight or Obesity: Phase 2b ENLIGHT Study},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-2636-p}
}
Kostenlos starten →